ATS 2020 Advance Program

11:00 Occupational Associated Interstitial Lung Diseases: Taking a Thorough Occupational History and Role of Industrial Hygienists in Accurate Diagnosis C.A. Redlich, MD, MPH, New Haven, CT 11:20 Cystic “Interstitial Lung Disease”: LAM and Beyond L.A. Ho, MD, Seattle, WA 11:40 Multidisciplinary Discussions for an Accurate Diagnosis: Case Discussion C.J. Scallan, MB BCh, Hamilton, Canada B. Collins, MD, Seattle, WA L.A. Ho, MD, Seattle, WA 12:50 LUNCH 1:20 Hypersensitivity Pneumonitis G. Raghu, MD, Seattle, WA 1:40 Hypersensitivity Pneumonitis: Challenges in Tools for Assessing Exposures and Tools for Antigen Assessment K.A.M. Johannson, MD, MPH, ATSF, Calgary, Canada 2:00 Lumping and Splitting: IPF and Progressive Fibrotic Lung Disease, Evolving Concepts G. Raghu, MD, Seattle, WA 2:10 Pulmonary Hypertension Among Patients with Fibrotic Lung Disease: Diagnosis and Treatment M. Humbert, MD, PhD, Bicetre, France 2:30 Sarcoidosis: Second and Third Line Treatment Agents V. Mihailovic-Vucinic, MD, Belgrade, Serbia 2:50 Break 3:00 Comorbid Conditions in ILD with Particular Focus on Lung Cancer: Diagnosis and Treatment D. Bouros, MD, PhD, Athens, Greece 3:20 Patient Centered Outcomes in ILD-Subgroups K.I. Aronson, MD, New York, NY 3:40 Treatment of IPF and Fibrotic Lung Disease: Update on Current Status and New Horizons L. Richeldi, PhD, MD, Rome, Italy CLINICAL • TRANSLATIONAL POSTGRADUATE COURSE PG20 DOES MY PATIENT HAVE ENVIRONMENTAL OR OCCUPATIONAL LUNG DISEASE? Pre-registration and additional fees required. Continental breakfast and box lunch included. Attendance is limited. Member: $350 In-Training Member: $200 Non-Member: $425 In-Training Non-Member: $300 Assemblies on Environmental, Occupational and Population Health; Clinical Problems; Section on Terrorism and Inhalation Disasters 8:00 a.m. - 4:00 p.m. Target Audience Clinicians, trainees and allied health personnel Objectives At the conclusion of this session, the participant will be able to: • diagnose lung disease due to or exacerbated by environmental and occupational exposures, leading to broader differential diagnoses, larger toolbox for managing this type of lung disease, and improved patient outcomes; • learn new findings about emerging exposures that cause lung disease, and have new strategies to provide counseling for patients on how to improve lung health through environmental interventions; • gain new strategies to assess for lung diseases due to environmental and occupational exposures, including using a multi-disciplinary approach with the input of radiologists and occupational health practitioners. The contribution of environmental and occupational exposures to the burden of many common lung diseases is under-appreciated. Failure to recognize these contributions can lead to misdiagnosis or suboptimal treatment. Many clinicians are often unsure of how to respond to patient questions regarding whether exposures caused their lung disease. This ATS 2020 • Philadelphia, PA 24 SATURDAY • MAY 16